Skip to Main Content

Gilead Sciences Inc

GILD Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

$GILD is featured in our Rob Bresnahan and Shelley Moore Capito strategies.

All Strategies
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of GILD by members of U.S. Congress

Politician Type Traded
Val T. Hoyle House / D Sale $1,001 - $15,000 Sep 23, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Jun 06, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 May 14, 2025
Jefferson Shreve House / R Sale $15,001 - $50,000 May 12, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 May 05, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 May 05, 2025
John Boozman Senate / R Sale (Full) $1,001 - $15,000 Apr 16, 2025
Jefferson Shreve House / R Purchase $15,001 - $50,000 Mar 31, 2025
Carol D. Miller House / R Purchase $1,001 - $15,000 Mar 10, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 Mar 07, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Dec 24, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 15, 2024
Val T. Hoyle House / D Purchase $1,001 - $15,000 Oct 29, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 May 29, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 May 10, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 May 10, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 May 10, 2024
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 May 08, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Apr 26, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Apr 05, 2024
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Apr 03, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 25, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Feb 13, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 05, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 03, 2023
HON. GREG STANTON House / D Sale $1,001 - $15,000 Oct 24, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Oct 02, 2023
HON. GREG STANTON House / D Purchase $1,001 - $15,000 Sep 26, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Jul 12, 2023
Zoe Lofgren House / D Sale $1,001 - $15,000 May 25, 2023
Daniel S. Goldman House / D Purchase $15,001 - $50,000 Mar 06, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Sep 29, 2022
Zoe Lofgren House / D Purchase $1,001 - $15,000 Sep 09, 2022
Ro Khanna House / D Sale $1,001 - $15,000 Aug 01, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 May 10, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 21, 2022
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Jan 20, 2022
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Jan 13, 2022
Ro Khanna House / D Sale None N/A
Ro Khanna House / D Sale None N/A
Jerry Moran Senate / R Sale (Full) $1,001 - $15,000 Dec 21, 2021
Jerry Moran Senate / R Sale (Full) $1,001 - $15,000 Dec 21, 2021
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Dec 07, 2021
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 21, 2021
GILD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
GILD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
GILD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in GILD holdings by institutional investors

Quarterly net insider trading by GILD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $2,780,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
  • $1,700,000 Jul 21, 2025 Issue: Health Issues Trade (domestic/foreign) Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
  • $1,662,000 Apr 21, 2025 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
  • $2,440,000 Jan 21, 2025 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark Budget/Appropriations Taxation/Internal Revenue Code
  • $2,050,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,530,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,740,000 Apr 18, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,680,000 Jan 23, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,390,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,440,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,490,000 Apr 14, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,520,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,372,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,620,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,980,000 Jan 19, 2022 Issue: None
  • $2,290,000 Oct 20, 2021 Issue: None
  • $1,380,000 Jul 20, 2021 Issue: None
  • $2,530,000 Apr 20, 2021 Issue: None
  • $1,510,000 Jan 20, 2021 Issue: None
  • $1,810,000 Oct 20, 2020 Issue: None
  • $1,260,000 Jul 20, 2020 Issue: None
  • $2,450,000 Apr 20, 2020 Issue: None
  • $1,300,000 Jan 21, 2020 Issue: None
  • $1,480,000 Oct 21, 2019 Issue: Budget/Appropriations Medicare/Medicaid Veterans Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Trade (domestic/foreign)
  • $1,080,000 Jul 22, 2019 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $1,860,000 Apr 23, 2019 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code Veterans Copyright/Patent/Trademark Health Issues
  • $700,000 Jan 22, 2019 Issue: Medicare/Medicaid Defense Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues Veterans Budget/Appropriations Indian/Native American Affairs Taxation/Internal Revenue Code
  • $680,000 Oct 22, 2018 Issue: Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Indian/Native American Affairs Budget/Appropriations
  • $800,000 Jul 20, 2018 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Foreign Relations Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Veterans Trade (domestic/foreign)
  • $810,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Veterans Foreign Relations Indian/Native American Affairs Budget/Appropriations Taxation/Internal Revenue Code
  • $900,000 Jan 22, 2018 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Veterans Foreign Relations
  • $810,000 Oct 20, 2017 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Veterans Copyright/Patent/Trademark Foreign Relations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Indian/Native American Affairs
  • $790,000 Jul 20, 2017 Issue: Pharmacy Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Veterans Trade (domestic/foreign) Indian/Native American Affairs Foreign Relations Taxation/Internal Revenue Code
  • $1,050,000 Apr 20, 2017 Issue: Law Enforcement/Crime/Criminal Justice Pharmacy Medicare/Medicaid Foreign Relations Health Issues Copyright/Patent/Trademark Indian/Native American Affairs Veterans Trade (domestic/foreign) Taxation/Internal Revenue Code Budget/Appropriations
  • $960,000 Jan 19, 2017 Issue: Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Budget/Appropriations Foreign Relations Trade (domestic/foreign) Law Enforcement/Crime/Criminal Justice Pharmacy
  • $780,000 Oct 20, 2016 Issue: Law Enforcement/Crime/Criminal Justice Pharmacy Medicare/Medicaid Foreign Relations Veterans Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Defense
  • $760,000 Jul 19, 2016 Issue: Medicare/Medicaid Foreign Relations Health Issues Pharmacy Trade (domestic/foreign) Veterans Defense Budget/Appropriations Copyright/Patent/Trademark
  • $980,000 Apr 18, 2016 Issue: Science/Technology Pharmacy Medicare/Medicaid Foreign Relations Veterans Health Issues Trade (domestic/foreign) Defense Budget/Appropriations Copyright/Patent/Trademark
  • $890,000 Jan 20, 2016 Issue: Science/Technology Pharmacy Medicare/Medicaid Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark Veterans Foreign Relations Defense Budget/Appropriations
  • $700,000 Oct 19, 2015 Issue: Pharmacy Medicare/Medicaid Veterans Health Issues Defense Trade (domestic/foreign) Foreign Relations Budget/Appropriations Copyright/Patent/Trademark Science/Technology
  • $550,000 Jul 20, 2015 Issue: Science/Technology Pharmacy Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Defense Foreign Relations Budget/Appropriations Trade (domestic/foreign)
  • $800,000 Apr 21, 2015 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Defense Copyright/Patent/Trademark
  • $620,000 Jan 19, 2015 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Defense Copyright/Patent/Trademark
  • $640,000 Oct 17, 2014 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Copyright/Patent/Trademark
  • $820,000 Jul 15, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
  • $810,000 Apr 18, 2014 Issue: Medicare/Medicaid Veterans Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark
  • $550,000 Jan 21, 2014 Issue: Health Issues Copyright/Patent/Trademark Veterans Medicare/Medicaid
  • $540,000 Oct 21, 2013 Issue: Health Issues Copyright/Patent/Trademark Veterans Medicare/Medicaid
  • $623,000 Aug 05, 2013 Issue: Health Issues Copyright/Patent/Trademark
  • $510,000 Jul 19, 2013 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
  • $320,000 Jan 22, 2013 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $370,000 Oct 22, 2012 Issue: Health Issues
  • $340,000 Jul 20, 2012 Issue: Health Issues
  • $560,000 Apr 20, 2012 Issue: Health Issues
  • $400,000 Jan 20, 2012 Issue: Health Issues
  • $370,000 Oct 20, 2011 Issue: Health Issues
  • $390,000 Jul 20, 2011 Issue: Health Issues
  • $500,000 Apr 20, 2011 Issue: Health Issues
  • $340,000 Jan 20, 2011 Issue: Health Issues
  • $350,000 Oct 20, 2010 Issue: Health Issues
  • $350,000 Jul 20, 2010 Issue: Health Issues
  • $480,000 Apr 20, 2010 Issue: Health Issues
  • $370,000 Jan 20, 2010 Issue: Health Issues
  • $350,000 Oct 20, 2009 Issue: Health Issues
  • $290,000 Jul 20, 2009 Issue: Health Issues
  • $270,000 Apr 20, 2009 Issue: Health Issues
  • $240,000 Jan 09, 2009 Issue: Health Issues
  • $240,000 Oct 28, 2008 Issue: Health Issues
  • $260,000 Oct 28, 2008 Issue: Health Issues
  • $260,000 Jun 25, 2008 Issue: Health Issues
  • $280,000 Feb 14, 2008 Issue: Health Issues
  • $380,000 Aug 14, 2007 Issue: Health Issues
  • $355,000 Feb 13, 2007 Issue: Health Issues
  • $455,000 Aug 14, 2006 Issue: Health Issues
  • $180,000 Apr 06, 2006 Issue: Health Issues
  • $60,000 Aug 24, 2005 Issue: Medical/Disease Research/Clinical Labs
  • $140,000 Aug 22, 2005 Issue: Health Issues
  • $20,000 Aug 15, 2005 Issue: Trade (domestic/foreign)
  • $40,000 Feb 09, 2005 Issue: None
  • $40,000 Sep 08, 2004 Issue: Health Issues
  • $100,000 Apr 12, 2004 Issue: Health Issues Pharmacy
  • $100,000 Aug 15, 2003 Issue: Health Issues Pharmacy
  • $100,000 Mar 03, 2003 Issue: Health Issues Pharmacy
  • $100,000 Aug 14, 2002 Issue: Health Issues Pharmacy
  • $60,000 Feb 14, 2002 Issue: Health Issues Pharmacy

GILD Estimated quarterly lobbying spending

GILD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
GILD Income Statement
GILD Balance Sheet
GILD Cash Flow
U.S. Patents

New GILD patent grants

  • Patent Title: Blister pack Sep. 23, 2025
  • Patent Title: Blister pack Aug. 05, 2025
  • Patent Title: Pouch Jul. 29, 2025
  • Patent Title: Carton Jun. 17, 2025
  • Patent Title: Blister pack May. 20, 2025
  • Patent Title: Blister pack Mar. 04, 2025
  • Patent Title: Blister pack Feb. 25, 2025
  • Patent Title: Blister pack May. 28, 2024
  • Patent Title: Blister pack May. 21, 2024
  • Patent Title: Pharmaceutical package Mar. 26, 2024
  • Patent Title: Pharmaceutical package Mar. 05, 2024
  • Patent Title: Blister pack May. 09, 2023
  • Patent Title: Blister pack May. 09, 2023
  • Patent Title: Blister pack packaging blank Feb. 28, 2023
  • Patent Title: Blister pack Dec. 27, 2022
  • Patent Title: Blister pack Dec. 27, 2022
  • Patent Title: Blister pack Aug. 23, 2022
  • Patent Title: Blister pack Aug. 16, 2022
  • Patent Title: Pharmaceutical package Jul. 26, 2022
  • Patent Title: Pharmaceutical package Jul. 26, 2022
  • Patent Title: Pharmaceutical package Jun. 21, 2022
  • Patent Title: Apoptosis signal-regulating kinase inhibitors Aug. 31, 2021
  • Patent Title: Apoptosis signal-regulating kinase inhibitors Aug. 11, 2020
  • Patent Title: 2-(n-pyrazolo)adenosines with application as adenosine a Apr. 16, 2019
  • Patent Title: Macrocyclic inhibitors of flaviviridae viruses Apr. 02, 2019
  • Patent Title: Process for preparing an a2a-adenosine receptor agonist and its polymorphs Mar. 19, 2019
  • Patent Title: Method for treating a pulmonary hypertension condition Jun. 12, 2018
  • Patent Title: 2′-chloro aminopyrimidinone and pyrimidine dione nucleosides May. 29, 2018
  • Patent Title: Methods for treating cancers May. 22, 2018
  • Patent Title: Substituted imidazo[1,2-a]pyrazines as syk inhibitors May. 15, 2018
  • Patent Title: Pyrazolo[1,5-a]pyrimidines for antiviral treatment May. 01, 2018
  • Patent Title: Benzimidazole and imadazopyridine carboximidamide compounds Apr. 24, 2018
  • Patent Title: Therapeutic compounds Apr. 24, 2018
  • Patent Title: Methods for treating Apr. 24, 2018
  • Patent Title: Compounds for the treatment of hiv Apr. 17, 2018
  • Patent Title: Apoptosis signal-regulating kinase inhibitors Apr. 17, 2018
  • Patent Title: Fxr (nr1h4) modulating compounds Apr. 10, 2018
  • Patent Title: Fxr (nr1h4) modulating compounds Apr. 03, 2018
  • Patent Title: Syk inhibitors Apr. 03, 2018
  • Patent Title: 1′-substituted carba-nucleoside analogs for antiviral treatment Mar. 27, 2018
  • Patent Title: Fused heterocyclic compounds as ion channel modulators Mar. 20, 2018
  • Patent Title: Apoptosis signal-regulating kinase inhibitors Mar. 06, 2018
  • Patent Title: Solid forms of an ask1 inhibitor Mar. 06, 2018
  • Patent Title: Modulators of pharmacokinetic properties of therapeutics Feb. 13, 2018
  • Patent Title: Therapeutic compounds Jan. 30, 2018
  • Patent Title: Cot modulators and methods of use thereof Jan. 30, 2018
  • Patent Title: Macrocyclic inhibitors of flaviviridae viruses Jan. 23, 2018
  • Patent Title: Apoptosis signal-regulating kinase inhibitor Jan. 23, 2018
  • Patent Title: Therapeutic compounds Jan. 23, 2018
  • Patent Title: Crystalline forms of an antiviral compound Jan. 09, 2018
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to GILD from public contracts

GILD News

Recent insights relating to GILD

CNBC Recommendations

Recent picks made for GILD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GILD

GILD Analyst Ratings

GILD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
GILD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $GILD stock a Buy, Sell, or Hold?

  • What is the price target for $GILD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

GILD Top Shareholders
Shareholder
Shares Held
GILD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $GILD stock?

  • Who owns the most shares of $GILD stock?

  • What funds own $GILD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

GILD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view GILD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About GILD

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

  • Address Foster City, CA
  • Market Cap 152.1 billion
  • Employees 17,600
  • Industrial Classification Biological Products, (No Disgnostic Substances)
Back To Top